Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma

The present study aimed to evaluate the efficacy of the real‐world use of axitinib and to develop a prognostic model for stratifying patients who could derive long‐term benefit from axitinib. This was a retrospective, descriptive study evaluating the efficacy of axitinib in patients with metastatic...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 2020-07, Vol.111 (7), p.2460-2471
Main Authors: Osawa, Takahiro, Kojima, Takahiro, Hara, Tomohiko, Sugimoto, Mikio, Eto, Masatoshi, Takeuchi, Ario, Minami, Keita, Nakai, Yasutomo, Ueda, Kosuke, Ozawa, Michinobu, Uemura, Motohide, Miyauchi, Yasuyuki, Ohba, Kojiro, Suzuki, Toshiro, Anai, Satoshi, Shindo, Tetsuya, Kusakabe, Naohisa, Tamura, Keita, Komiyama, Motokiyo, Goto, Takayuki, Yokomizo, Akira, Kohei, Naoki, Kashiwagi, Akira, Murakami, Masaya, Sazuka, Tomokazu, Yasumoto, Hiroaki, Iwamoto, Hideto, Mitsuzuka, Koji, Morooka, Daichi, Shimazui, Toru, Yamamoto, Yoshiaki, Ikeshiro, Suguru, Nakagomi, Hiroshi, Morita, Ken, Tomida, Ryotaro, Mochizuki, Tango, Inoue, Takamitsu, Kitamura, Hiroshi, Yamada, Shuhei, Ito, Yoichi M., Murai, Sachiyo, Nishiyama, Hiroyuki, Shinohara, Nobuo
Format: Article
Language:English
Subjects:
axitinib
Cancer therapies
Clinical trials
Drug dosages
Immunotherapy
Kidney cancer
Laboratories
Lymphocytes
Medical prognosis
Metastases
Metastasis
metastatic
Neutrophils
Oncology
Original
Patients
Population studies
prognostic factor
Renal cell carcinoma
Risk groups
risk model
Survival analysis
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The present study aimed to evaluate the efficacy of the real‐world use of axitinib and to develop a prognostic model for stratifying patients who could derive long‐term benefit from axitinib. This was a retrospective, descriptive study evaluating the efficacy of axitinib in patients with metastatic renal cell carcinoma that had been treated with 1 or 2 systemic antiangiogenic therapy regimens at 1 of 36 hospitals belonging to the Japan Urologic Oncology Group between January 2012 and February 2019. The primary outcome was overall survival (OS). Using a split‐sample method, candidate variables that exhibited significant relationships with OS were chosen to create a model. The new model was validated using the rest of the cohort. In total, 485 patients were enrolled. The median OS was 34 months in the entire study population, whereas it was not reached, 27 months, and 14 months in the favorable, intermediate, and poor risk groups, respectively, according to the new risk classification model. The following 4 variables were included in the final risk model: the disease stage at diagnosis, number of metastatic sites at the start of axitinib therapy, serum albumin level, and neutrophil : lymphocyte ratio. The adjusted area under the curve values of the new model at 12, 36, and 60 months were 0.77, 0.82, and 0.82, respectively. The efficacy of axitinib in routine practice is comparable or even superior to that reported previously. The patients in the new model’s favorable risk group might derive a long‐term survival benefit from axitinib treatment. The accuracy of the overall survival predictions made after the initiation of axitinib treatment, area under the curve (AUC) values were calculated for each model. The adjusted AUC values at 12, 36, and 60 months after the initiation of axitinib were 0.77, 0.82, and 0.82, respectively, for the axitinib treatment prediction model, and 0.69, 0.67 and 0.56, respectively, for the International Metastatic Renal Cell Carcinoma Database Consortium model.
ISSN:1347-9032
1349-7006
DOI:10.1111/cas.14449